Latest News - Veeva Systems
Top Corporates Hub
Veeva Systems
Guidance Up, Trend Intact: Veeva Is Today's Double-Confirmation Stock
23.10.2026 08:03
For questions about this article or underlying research, email help@trefis.com.
How Unusual Is Box's Latest Profit Margin?
22.10.2026 16:16
For questions about this article or underlying research, email help@trefis.com.
Global Decentralized Clinical Trials Market Size, Share, Growth Trends, and Forecast 2026-2035 | Clinical Trials leave the Clinic as the Decentralized Model Heads for a $28.4bn Market
22.10.2026 13:23
New Report values decentralised clinical trials at $8bn in 2025, with hybrid models taking 54.1% and North America 44.2%, though data integrity and patchy regulation across regions still trouble IQVIA, Medidata, Medable and Veeva SystemsDublin, Oct. 22, 2026 (GLOBE NEWSWIRE) -- "Decentralized Clinical Trials Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2026-2035" has been added to ResearchAndMarkets.com's offering. The Global Decentralized Clinical Trials Market was
iOnctura appoints Paul Sekhri as Chair of its Board of Directors
15.10.2026 07:30
Paul Sekhri is a life science executive with more than 35 years of experience building and leading companies from early development through commercializationAppointment comes as iOnctura prepares for late-stage development of roginolisib, with its two randomized studies fully enrolledStrengthens iOnctura’s Board with extensive experience in company building, strategic transactions and financing GENEVA, AMSTERDAM and CAMBRIDGE, Mass., Oct. 15, 2026 (GLOBE NEWSWIRE) -- iOnctura, a clinical-stage p
Is Veeva Systems (VEEV) Quietly Redefining Clinical Tech Moats With IQVIA Deal And Basics Uptake?
14.10.2026 19:17
In recent days, IQVIA announced it has selected Veeva Systems’ CTMS, eTMF, Study Startup, and Site Connect as enterprise-standard applications across its clinical development studies, extending their earlier EDC partnership and making Veeva’s full clinical technology stack available to sponsors. At the same time, Veeva reported that more than 175 emerging biotechs are now using its Veeva Basics suite to build scalable, end-to-end digital foundations for clinical, regulatory, quality,...
Veeva Systems (VEEV) Becomes Default Clinical Software Across A Major Research Partner
14.10.2026 18:15
Veeva Systems (NYSE:VEEV) said IQVIA will adopt Veeva's core clinical applications as enterprise standards across all IQVIA studies. The expanded agreement covers Veeva Clinical Trial Management System, eTMF, Study Startup, and Site Connect for IQVIA's global research operations. The move deepens Veeva's role in IQVIA's clinical execution workflow and broadens its reach across contract research and biopharma customers. IQVIA's decision to standardize on Veeva's clinical suite reshapes how...
Veeva Stock Breaks Out As Big Money Grabs Exposure To The AI Software Play
14.10.2026 17:11
Veeva Systems stock moves above a buy point in its early-stage chart pattern.
IQVIA Selects Veeva Clinical Operations Applications
13.10.2026 11:03
IQVIA (NYSE: IQV) and Veeva Systems (NYSE: VEEV) today announced an expansion of their partnership with the selection of Veeva CTMS, eTMF, Study Startup, and Site Connect as enterprise standard applications that will be used across IQVIA clinical development studies. This extends the previously announced EDC partnership.
Reasons to Hold Veeva Systems Stock in Your Portfolio for Now
09.10.2026 13:43
VEEV's strong second-quarter results, Vault CRM migrations and AI expansion support growth, while market saturation remains a key concern.
Veeva (VEEV) Stock May Be 11% Below Fair Value After Biotech Adoption News
09.10.2026 03:17
Veeva Systems has delivered a mixed share price story over recent years, which puts the focus firmly on whether the current market value lines up with the cash it can generate. With the stock now back near the spotlight after a solid multi year gain, the question is how well that price matches the stream of cash flows investors are effectively paying for. Over the past 3 years the stock has returned 31.9%, so a meaningful amount of investor capital now depends on whether the underlying cash...
Veeva Summit to Showcase AI Innovations and the Leaders Transforming R&D and Quality
08.10.2026 11:03
At Veeva R&D and Quality Summit on October 20-21 in Boston, Veeva Systems (NYSE: VEEV) will bring together leading biopharmas, emerging biotechs, CROs, and sites — including Duke University, Eli Lilly and Company, Pfizer, Sanofi, Tolmar, UCB, and the University of Pennsylvania — to explain how they are driving new ways of working across drug development and quality.
Veeva Summit to Showcase AI Innovations and the Leaders Transforming R&D and Quality
08.10.2026 11:03
At Veeva R&D and Quality Summit on October 20-21 in Boston, Veeva Systems (NYSE: VEEV) will bring together leading biopharmas, emerging biotechs, CROs, and sites — including Duke University, Eli Lilly and Company, Pfizer, Sanofi, Tolmar, UCB, and the University of Pennsylvania — to explain how they are driving new ways of working across drug development and quality.
Veeva Systems (NYSE:VEEV): Strong Growth Meets a High-Quality Technical Setup
08.10.2026 10:20
Veeva Systems pairs strong growth and margins with a consolidation breakout setup; valuation is the key risk to watch for growth stock investors.
Why Is Veeva Systems (VEEV) Drawing Attention After Reaching 175 Biotechs?
08.10.2026 09:13
Veeva Systems (NYSE:VEEV) reported that more than 175 emerging biotech companies now use its Veeva Basics platform for drug development. The firm said its Data Quality System has processed and cleaned information for over 1 million subjects across more than 1,000 clinical studies. Management framed both updates as steps toward more automated clinical trial data handling for life sciences customers. The rapid Veeva Basics uptake and DQS scale are one chapter in a broader Veeva Systems story...
Veeva DQS Cleans Data for More Than 1 Million Subjects Across Over 1,000 Studies
06.10.2026 11:03
Veeva Systems (NYSE: VEEV) today announced that Veeva DQS (Data Quality System) has aggregated and cleaned data for more than 1 million subjects in more than 1,000 studies to accelerate the delivery of analysis-ready data and trial insights. With more than 500,000 automated queries, Veeva DQS has saved thousands of hours in data reconciliation for sites and sponsors.
Brokers Suggest Investing in Veeva (VEEV): Read This Before Placing a Bet
29.09.2026 12:30
Based on the average brokerage recommendation (ABR), Veeva (VEEV) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?
Veeva Systems: Excellent Execution, But Upside Potential Has Waned (Rating Downgrade)
27.09.2026 06:25
Veeva Systems was downgraded to neutral after a 40%+ rally as valuation looks stretched despite strong growth and Falcon AI demand. Click for more on VEEV stock.
How Investors Are Reacting To Veeva Systems (VEEV) Expanding Agentic AI And Winning New Pharma Clients
25.09.2026 06:10
In recent days, Veeva Systems has rolled out new AI-powered tools such as Veeva Study Builder Agent and Veeva Falcon Router, while announcing major customer wins including Oxford Biomedica adopting Veeva Quality Cloud and Amgen planning a global deployment of Veeva Vault CRM. Together, these developments highlight Veeva’s push to embed agentic AI across clinical, safety, quality, and commercial workflows, reinforcing its role as an end-to-end software partner for life sciences...
New Veeva Study Builder Agent to Configure Clinical Studies in as Little as One Day
24.09.2026 11:03
Veeva Systems (NYSE: VEEV) today announced Veeva Study Builder Agent, a new AI solution that configures Veeva EDC and Veeva DQS (Data Quality System) directly from a study protocol. By reusing an organization's existing standards and leveraging the CDISC Unified Study Definitions Model (USDM), the agent ensures faster, more deterministic study builds.
Quality Management System Software Market Forecasts Growth from $11.73B (2026) to $20.43B by 2031, Profiling Veeva Systems, Siemens, PTC, SAP, Oracle & 15 Others
24.09.2026 10:29
The global Quality Management System (QMS) software market is projected to grow from USD 11.73 billion in 2026 to USD 20.43 billion by 2031, at an 11.7% CAGR. Growth is driven by cloud-based QMS platforms, AI-powered quality analytics, automated compliance workflows and integration with ERP, MES and PLM systems. SMEs are the fastest-growing customer segment, while document control and management holds the largest market share. North America leads the market, and Asia Pacific is the fastest-growi